ClinicalTrials.gg
CompletedNCT02490475Updated May 17, 2017Results posted

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

A Phase 1 interventional study of Docetaxel and RhuMab 2C4 in Solid Tumor, sponsored by Hoffmann-La Roche. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-17.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of rhuMab 2C4 (Perjeta) and docetaxel (Taxotere) in participants with advanced solid tumors that have progressed during or after standard therapy, or for which no standard therapy is available. Participants will be enrolled and evaluated for dose-limiting toxicities (DLTs) in escalating-dose cohorts in order to determine the maximum tolerated dose (MTD).

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults at least 18 years of age
  • Easter Cooperative Oncology Group () performance status of 0 or 1
  • at least 12 weeks
  • Locally advanced or solid tumor with at least 1 , which has progressed during/after standard therapy
  • Human epidermal growth factor receptor 2 ()-negative among participants with breast cancer
  • Negative pregnancy test or use of an adequate method among women of
  • Adequate hematologic, hepatic, and renal function
  • Signed , histologically or cytologicall confirmed advanced solid tumor, adequate cardiac function as documented by >50% by ECHO or MUGA

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of central nervous system (CNS)
  • Prior chemotherapy, radiotherapy, or immunotherapy within 4 weeks, or hormone therapy within 2 weeks of study Day 1
  • History of neuropathy Grade 2 or worse, or any unresolved residual chemotherapy effects
  • Prior -active agents or docetaxel
  • Any agent within 28 days of study drug
  • Prior cumulative doxorubicin dose greater than (>) 360 mg/m\^2 or equivalent
  • Significant cardiovascular disease
  • Active/uncontrolled concurrent illness or infection-
  • Major surgery or trauma within 4 weeks of study Day 1
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)

    Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.

    Drug: Docetaxel · Drug: RhuMab 2C4

  • Experimental
    RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)

    Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.

    Drug: Docetaxel · Drug: RhuMab 2C4

  • Experimental
    RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)

    Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.

    Drug: Docetaxel · Drug: RhuMab 2C4

Interventions

  • Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

    Also known as: Taxotere

  • Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

    Also known as: Omnitarg

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab

    A prior dose level was defined as an MTD if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs). If there were no DLTs or DLTs were seen in less than (\<) 2 participants in the highest dose level, that was considered as MTD. Participants received escalating doses of docetaxel and pertuzumab until DLTs were observed. DLTs were defined as any of the following: 1) Any non-hematological toxicity ≥ Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management, 2) Grade 4 neutropenia lasting greater than (\>) 7 days, 3) Febrile neutropenia, 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion or 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds.

    Time frame: Cycle 1 Up to Day 15

Secondary outcomes

  1. Plasma Decay Half Life (t1/2) for Pertuzumab in Combination With Docetaxel

    The biological half-life or terminal half-life of pertuzumab is the time in days it takes for it to lose half of its pharmacologic activity.

    Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22

  2. Maximum Observed Plasma Concentration (Cmax) for Pertuzumab in Combination With Docetaxel

    Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as micrograms per milliliter (μg/mL).

    Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22

  3. Area Under the Concentration Curve From Time Zero to the Last Visit (AUC [0-last]) for Pertuzumab in Combination With Docetaxel

    The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (μg\*day/mL).

    Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22

  4. AUC From Time Zero to Infinity (AUC [0-infinity]) for Pertuzumab in Combination With Docetaxel

    The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as μg\*day/mL.

    Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22

  5. Clearance (Cl) of Pertuzimab in Combination With Docetaxel

    Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).

    Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22

  6. Volume of Distribution (Vz) at Steady State of Pertuzumab in Combination With Docetaxel

    The volume of distribution at steady state (Vz), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.

    Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22

  7. Mean Residence Time (MRT) of Pertuzumab

    MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.

    Time frame: Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22

  8. Percentage of Participants by Best Overall Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria

    Best Overall response was evaluated as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). CR: complete disappearance of all target lesions. PR: at least a 30 percent (%) decrease in the sum of the longest diameters. SD: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameters since the treatment started. PD: at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters of the target lesions recorded since the treatment started, including screening, or the appearance of one or more new lesions. If participants withdrew due to insufficient therapeutic response or death and had no tumor measurements at the final visit, they were counted under progressive disease for final visit.

    Time frame: Weeks 7 (Cycle 2),13 (Cycle 4) and Final Visit Up to 22 weeks

  9. Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) by Category of Decrease and Timepoint

    Ejection fraction (EF) is the fraction of outbound blood pumped from the heart with each heartbeat. It is commonly measured by echocardiogram and serves as a general measure of a person's cardiac function. Changes in LVEF were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria. The decrease in LVEF has been categorized as follows: A) Increase, no change, decrease from baseline less than (\<) 10%; B) Absolute value \<50% and decrease from baseline greater than or equal to (≥) 10%; C) Absolute value \<50% and decrease from baseline≥15% ; D) Other. If participants withdrew due to insufficient therapeutic response or death and had no tumor measurements at the final visit, they were counted under progressive disease for final visit.

    Time frame: Baseline, Weeks 7(Cycle 2), 13 (Cycle 4) and Final Visit Up to Week 22

  10. t1/2 for Docetaxel Alone and in Combination With Pertuzumab

    The biological half-life or terminal half-life of docetaxel is the time in hours it takes for it to lose half of its pharmacologic activity. Data for "docetaxel alone" arms were analyzed for the timepoints on Day 1 prior to the administration of pertuzumab. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

    Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose

  11. Tmax for Docetaxel Alone and in Combination With Pertuzumab

    Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; Data for "docetaxel alone" arms were analyzed for the timepoints on Day 1 prior to the administration of pertuzumab. When the rate of absorption equals the rate of elimination. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

    Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose

  12. Cmax for Docetaxel Alone and in Combination With Pertuzumab

    Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as nanograms per milliliter (ng/mL). The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

    Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose

  13. AUC(0-∞) for Docetaxel Alone and in Combination With Pertuzumab

    The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as ng\*h/mL. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

    Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose

  14. Vss for Docetaxel Alone and in Combination With Pertuzumab

    The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

    Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose

  15. CL for Docetaxel Alone and in Combination With Pertuzumab

    Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per hour per meter squared (mL/h/m\^2). The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

    Time frame: Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose

  16. Number of Participants With DLTs

    DLTs were defined as any of the following: 1) Any non-hematological toxicity greter than or equal to (≥) Grade 3 according t0 CTCAE version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management, 2) Grade 4 neutropenia lasting greater than (\>) 7 days, 3) Febrile neutropenia, 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion or 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds.

    Time frame: From Baseline until 4 weeks after the end of treatment

07

Results

Posted Nov 25, 2015

Participant flow

Period 1: First 6 Cycles
Participant flow — Period 1: First 6 Cycles
MilestoneDocetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420
Started6265
Completed0000
Not completed6265
Withdrew: Adverse event2101
Withdrew: Insufficient therapeutic response2022
Withdrew: Refused treatment1000
Withdrew: Completed 6 cycles of therapy1142
Period 2: Extension Phase
Participant flow — Period 2: Extension Phase
MilestoneDocetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420
Started1031
Completed0000
Not completed1031
Withdrew: Insufficient therapeutic response1020
Withdrew: Refused treatment0001
Withdrew: Adverse event0010

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab

A prior dose level was defined as an MTD if at a certain dose level, there were greater than or equal to (≥) 2 out of 6 participants who had Dose Limiting Toxicities (DLTs). If there were no DLTs or DLTs were seen in less than (\<) 2 participants in the highest dose level, that was considered as MTD. Participants received escalating doses of docetaxel and pertuzumab until DLTs were observed. DLTs were defined as any of the following: 1) Any non-hematological toxicity ≥ Grade 3 according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management, 2) Grade 4 neutropenia lasting greater than (\>) 7 days, 3) Febrile neutropenia, 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion or 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds.

Time frame:
Cycle 1 Up to Day 15
Reported as:
Number · mg/m^2
Maximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab
mg/m^2Entire Study Population
Maximum Tolerated Dose (MTD) of Docetaxel in Combination of Pertuzumab75.0
SecondaryPlasma Decay Half Life (t1/2) for Pertuzumab in Combination With Docetaxel

The biological half-life or terminal half-life of pertuzumab is the time in days it takes for it to lose half of its pharmacologic activity.

Time frame:
Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Reported as:
Median · days
Plasma Decay Half Life (t1/2) for Pertuzumab in Combination With Docetaxel
daysPertuzumab 1050Pertuzumab 840Pertuzumab 420
Cycle 1 (n=8,11,0)12.65 (7.80 to 19.59)11.65 (6.95 to 25.96)NA (NA to NA)
Cycle 2 (n=7,0,10)19.02 (9.02 to 49.63)NA (NA to NA)18.46 (8.85 to 42.00)
SecondaryMaximum Observed Plasma Concentration (Cmax) for Pertuzumab in Combination With Docetaxel

Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as micrograms per milliliter (μg/mL).

Time frame:
Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Reported as:
Mean · μg/mL
Maximum Observed Plasma Concentration (Cmax) for Pertuzumab in Combination With Docetaxel
μg/mLPertuzumab 1050Pertuzumab 840Pertuzumab 420
Cycle 1 (n=8,11,0)301.0 ± 93.0255.0 ± 84.0NA ± NA
Cycle 2 (n=7,0,10)368.0 ± 79.0NA ± NA150.0 ± 43.0
SecondaryArea Under the Concentration Curve From Time Zero to the Last Visit (AUC [0-last]) for Pertuzumab in Combination With Docetaxel

The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (μg\*day/mL).

Time frame:
Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Reported as:
Mean · μg*day/mL
Area Under the Concentration Curve From Time Zero to the Last Visit (AUC [0-last]) for Pertuzumab in Combination With Docetaxel
μg*day/mLPertuzumab 1050Pertuzumab 840Pertuzumab 420
Cycle 1 (n=8,11,0)2390 ± 5841749 ± 543NA ± NA
Cycle 2 (n=7,0,10)3500 ± 551NA ± NA1491 ± 472
SecondaryAUC From Time Zero to Infinity (AUC [0-infinity]) for Pertuzumab in Combination With Docetaxel

The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as μg\*day/mL.

Time frame:
Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Reported as:
Mean · μg*day/mL
AUC From Time Zero to Infinity (AUC [0-infinity]) for Pertuzumab in Combination With Docetaxel
μg*day/mLPertuzumab 1050Pertuzumab 840Pertuzumab 420
Cycle 1 (n=8,11,0)3951 ± 9192796 ± 967NA ± NA
Cycle 2 (n=7,0,10)6856 ± 2335NA ± NA2762 ± 892
SecondaryClearance (Cl) of Pertuzimab in Combination With Docetaxel

Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).

Time frame:
Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Reported as:
Mean · mL/day
Clearance (Cl) of Pertuzimab in Combination With Docetaxel
mL/dayPertuzumab 1050Pertuzumab 840Pertuzumab 420
Cycle 1 (n=8,11,0)282 ± 83329 ± 97NA ± NA
Cycle 2 (n=7,0,10)167 ± 49NA ± NA169 ± 60
SecondaryVolume of Distribution (Vz) at Steady State of Pertuzumab in Combination With Docetaxel

The volume of distribution at steady state (Vz), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.

Time frame:
Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Reported as:
Mean · mL
Volume of Distribution (Vz) at Steady State of Pertuzumab in Combination With Docetaxel
mLPertuzumab 1050Pertuzumab 840Pertuzumab 420
Cycle 1 (n=8,11,0)5214 ± 13865355 ± 1680NA ± NA
Cycle 2 (n=7,0,10)4672 ± 1221NA ± NA4233 ± 1555
SecondaryMean Residence Time (MRT) of Pertuzumab

MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.

Time frame:
Cycle1: Day 2 Pre-dose and 15 minutes, 1.5, 4 and 8 hours Post-dose, and Days 3, 6, 9 and 16; Cycle 2: Day 1 Pre-dose and 15 minutes Post-dose on Days 1, 8, 15 and 22
Reported as:
Mean · days
Mean Residence Time (MRT) of Pertuzumab
daysPertuzumab 1050Pertuzumab 840Pertuzumab 420
Cycle 1 (n=8,11,0)17.8 ± 5.815.8 ± 6.7NA ± NA
Cycle 2 (n=7,0,10)29.5 ± 18.5NA ± NA25.8 ± 13.2
SecondaryPercentage of Participants by Best Overall Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria

Best Overall response was evaluated as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). CR: complete disappearance of all target lesions. PR: at least a 30 percent (%) decrease in the sum of the longest diameters. SD: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameters since the treatment started. PD: at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters of the target lesions recorded since the treatment started, including screening, or the appearance of one or more new lesions. If participants withdrew due to insufficient therapeutic response or death and had no tumor measurements at the final visit, they were counted under progressive disease for final visit.

Time frame:
Weeks 7 (Cycle 2),13 (Cycle 4) and Final Visit Up to 22 weeks
Reported as:
Number · percentage of participants
Percentage of Participants by Best Overall Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
percentage of participantsDocetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420
Cycle 2: CR (n=6,1,6,4)0.00.00.00.0
Cycle 2:PR (n=6,1,6,4)0.00.00.00.0
Cycle 2:SD (n=6,1,6,4)83.3100.083.375.0
Cycle 2:PD (n=6,1,6,4)16.7016.725.0
Cycle 2:Missing (n=6,1,6,4)0.00.00.00.0
Cycle 4:CR (n=5,1,5,3)0.00.00.00.0
Cycle 4:PR (n=5,1,5,3)0.00.020.00
Cycle 4:SD (n=5,1,5,3)80.0100.040.066.7
Cycle 4:PD (n=5,1,5,3)20.00.040.033.3
Cycle 4:Missing (n=5,1,5,3)0.00.00.00.0
Final visit:CR (n=6,2,6,5)0.00.00.00.0
Final visit:PR (n=6,2,6,5)0.00.016.70.0
Final visit:SD (n=6,2,6,5)33.350.033.320.0
Final visit:PD (n=6,2,6,5)50.00.050.060.0
Final visit:Missing (n=6,2,6,5)16.750.00.020.0
SecondaryPercentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) by Category of Decrease and Timepoint

Ejection fraction (EF) is the fraction of outbound blood pumped from the heart with each heartbeat. It is commonly measured by echocardiogram and serves as a general measure of a person's cardiac function. Changes in LVEF were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria. The decrease in LVEF has been categorized as follows: A) Increase, no change, decrease from baseline less than (\<) 10%; B) Absolute value \<50% and decrease from baseline greater than or equal to (≥) 10%; C) Absolute value \<50% and decrease from baseline≥15% ; D) Other. If participants withdrew due to insufficient therapeutic response or death and had no tumor measurements at the final visit, they were counted under progressive disease for final visit.

Time frame:
Baseline, Weeks 7(Cycle 2), 13 (Cycle 4) and Final Visit Up to Week 22
Reported as:
Number · percentage of participants
Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) by Category of Decrease and Timepoint
percentage of participantsDocetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420
Cycle 2: A (n=6,1,6,4)83.3100.0100.0100.0
Cycle 2: B (n=6,1,6,4)0.00.00.00.0
Cycle 2: C (n=6,1,6,4)0.00.00.00.0
Cycle 2: D (n=6,1,6,4)16.70.00.00.0
Cycle 4: A (n=5,1,4,3)100.0100.075.0100.0
Cycle 4: B (n=5,1,4,3)0.00.025.00.0
Cycle 4: C (n=5,1,4,3)0.00.00.00.0
Cycle 4: D (n=5,1,4,3)0.00.00.00.0
Final Visit: A (n=3,1,5,2)66.7100.080.0100.0
Final Visit: B (n=3,1,5,2)0.00.00.00.0
Final Visit: C (n=3,1,5,2)0.00.00.00.0
Final Visit: D (n=3,1,5,2)33.30.020.00.0
Secondaryt1/2 for Docetaxel Alone and in Combination With Pertuzumab

The biological half-life or terminal half-life of docetaxel is the time in hours it takes for it to lose half of its pharmacologic activity. Data for "docetaxel alone" arms were analyzed for the timepoints on Day 1 prior to the administration of pertuzumab. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

Time frame:
Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Reported as:
Median · days
t1/2 for Docetaxel Alone and in Combination With Pertuzumab
daysDocetaxel 60 AloneDocetaxel 60 + Pertuzumab 1050Docetaxel 75 AloneDocetaxel 75+ Pertuzumab 420Docetaxel 100 AloneDocetaxel 100 + Pertuzumab 420
Cycle 1 (n=6,0,6,0,5,0)17.7 (7.31 to 22.7)NA (NA to NA)12.0 (9.56 to 19.4)NA (NA to NA)8.92 (7.49 to 13.5)NA (NA to NA)
Cycle 2(n=0,6,0,6,0,4)NA (NA to NA)19.7 (12.5 to 27.1)NA (NA to NA)13.8 (9.62 to 23.8)NA (NA to NA)11.8 (8.04 to 21.4)
SecondaryTmax for Docetaxel Alone and in Combination With Pertuzumab

Tmax is defined as the time after administration of a drug when the maximum plasma concentration is reached; Data for "docetaxel alone" arms were analyzed for the timepoints on Day 1 prior to the administration of pertuzumab. When the rate of absorption equals the rate of elimination. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

Time frame:
Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Reported as:
Median · days
Tmax for Docetaxel Alone and in Combination With Pertuzumab
daysDocetaxel 60 AloneDocetaxel 60 + Pertuzumab 1050Docetaxel 75 AloneDocetaxel 75 + Pertuzumab 420Docetaxel 100 AloneDocetaxel 100 + Pertuzumab 420
Cycle 1 (n=6,0,6,0,5,0)0.50 (0.50 to 0.90)NA (NA to NA)0.50 (0.50 to 0.90)NA (NA to NA)0.90 (0.90 to 0.90)NA (NA to NA)
Cycle 2 (n=0,6,0,6,0,4)NA (NA to NA)0.90 (0.50 to 1.25)NA (NA to NA)0.90 (0.50 to 0.90)NA (NA to NA)0.70 (0.50 to 0.90)
SecondaryCmax for Docetaxel Alone and in Combination With Pertuzumab

Cmax refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and prior to the administration of a second dose and is measures as nanograms per milliliter (ng/mL). The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

Time frame:
Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Reported as:
Mean · ng/mL
Cmax for Docetaxel Alone and in Combination With Pertuzumab
ng/mLDocetaxel 60 AloneDocetaxel 60 + Pertuzumab 1050Docetaxel 75 AloneDocetaxel 75 + Pertuzumab 420Docetaxel 100 AloneDocetaxel 100 + Pertuzumab 420
Cycle 1 (n=6,0,6,0,5,0)1642 ± 274NA ± NA3128 ± 895NA ± NA5450 ± 1867NA ± NA
Cycle 2 (n=0,6,0,6,0,4)NA ± NA1695 ± 331NA ± NA2722 ± 912NA ± NA4705 ± 1871
SecondaryAUC(0-∞) for Docetaxel Alone and in Combination With Pertuzumab

The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as ng\*h/mL. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

Time frame:
Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Reported as:
Mean · ng*h/mL
AUC(0-∞) for Docetaxel Alone and in Combination With Pertuzumab
ng*h/mLDocetaxel 60 AloneDocetaxel 60 + Pertuzumab 1050Docetaxel 75 AloneDocetaxel 75 + Pertuzumab 420Docetaxel 100 AloneDocetaxel 100 + Pertuzumab 420
Cycle 1 (n=6,0,6,0,5,0)1838 ± 244NA ± NA3744 ± 1304NA ± NA5930 ± 2137NA ± NA
Cycle 2 (n=0,6,0,6,0,4)NA ± NA1734 ± 409NA ± NA3496 ± 1211NA ± NA5218 ± 2216
SecondaryVss for Docetaxel Alone and in Combination With Pertuzumab

The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

Time frame:
Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Reported as:
Mean · mL/m^2
Vss for Docetaxel Alone and in Combination With Pertuzumab
mL/m^2Docetaxel 60 AloneDocetaxel 60 + Pertuzumab 1050Docetaxel 75 AloneDocetaxel 75 + Pertuzumab 420Docetaxel 100 AloneDocetaxel 100 + Pertuzumab 420
Cycle 1 (n=6,0,6,0,5,0)786981 ± 218139NA ± NA410174 ± 184216NA ± NA254233 ± 85054NA ± NA
Cycle 2 (n=0,6,0,6,0,4)NA ± NA1023569 ± 335711NA ± NA566759 ± 361946NA ± NA428863 ± 283977
SecondaryCL for Docetaxel Alone and in Combination With Pertuzumab

Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per hour per meter squared (mL/h/m\^2). The pharmacokinetic parameters were derived by non-compartmental methods using WinNonLin version 5.0.1.

Time frame:
Cycles 1 and 2: Pre-dose, 30 and 55 minutes during dosing, 15 minutes, 30 minutes, 1, 2, 4, 8, and 23 hours Post-dose
Reported as:
Mean · mL/h/m^2
CL for Docetaxel Alone and in Combination With Pertuzumab
mL/h/m^2Docetaxel 60 AloneDocetaxel 60 + Pertuzumab 1050Docetaxel 75 AloneDocetaxel 75 + Pertuzumab 420Docetaxel 100 AloneDocetaxel 100 + Pertuzumab 420
Cycle 1 (n=6,0,6,0,5,0)33128 ± 4396NA ± NA22013 ± 7031NA ± NA18913 ± 7245NA ± NA
Cycle 2 (n=0,6,0,6,0,4)NA ± NA35813 ± 6216NA ± NA23747 ± 8175NA ± NA22976 ± 12679
SecondaryNumber of Participants With DLTs

DLTs were defined as any of the following: 1) Any non-hematological toxicity greter than or equal to (≥) Grade 3 according t0 CTCAE version 3.0 except for fever, chills and flu-like symptoms, in spite of adequate toxicity management, 2) Grade 4 neutropenia lasting greater than (\>) 7 days, 3) Febrile neutropenia, 4) Thrombocytopenia Grade 4 or any thrombocytopenia requiring platelet transfusion or 5) Any subjectively intolerable toxicity felt by the investigator to be related to either one of the compounds.

Time frame:
From Baseline until 4 weeks after the end of treatment
Reported as:
Number · number of participants
Number of Participants With DLTs
number of participantsDocetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420
Number of Participants With DLTs0202

Adverse events

Collected over Adverse events were continuously monitored from Screening until 4 weeks after the final visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel 60 Plus (+) Pertuzumab 1050—3/6 (50%)6/6 (100%)
Docetaxel 75 + Pertuzumab 1050—2/2 (100%)2/2 (100%)
Docetaxel 75 + Pertuzumab 420—0/6 (0%)6/6 (100%)
Docetaxel 100 + Pertuzumab 420—3/5 (60%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventDocetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420
DiarrhoeaGastrointestinal disorders0/61/20/60/5
Febrile neutropeniaBlood and lymphatic system disorders0/61/20/61/5
FatigueGeneral disorders0/61/20/60/5
NauseaGastrointestinal disorders0/60/20/61/5
VomitingGastrointestinal disorders0/60/20/61/5
PyrexiaGeneral disorders1/60/20/60/5
Lower respiratory tract infectionInfections and infestations1/60/20/60/5
Urinary tract infectionInfections and infestations1/60/20/60/5
ParalysisNervous system disorders1/60/20/60/5
HypertensionVascular disorders1/60/20/60/5
Most frequent other events
Showing 10 of 109
Most frequent other events
EventDocetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420
DiarrhoeaGastrointestinal disorders5/62/25/64/5
NauseaGastrointestinal disorders5/62/25/64/5
FatigueGeneral disorders5/62/26/65/5
AlopeciaSkin and subcutaneous tissue disorders0/60/25/64/5
EpistaxisRespiratory, thoracic and mediastinal disorders1/60/25/61/5
Abdominal painGastrointestinal disorders4/60/20/62/5
DysgeusiaNervous system disorders4/61/24/60/5
RashSkin and subcutaneous tissue disorders4/60/22/62/5
ArthralgiaMusculoskeletal and connective tissue disorders2/60/24/61/5
StomatitisGastrointestinal disorders1/60/20/63/5

Baseline characteristics

The Intent-To-Treat (ITT) Population included all participants who received any amount of the study medication.

Age, Continuous
Age, Continuous(years)Docetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420Total
Mean58.2 ± 5.3862.5 ± 9.1959.5 ± 6.0645.0 ± 20.2155.6 ± 12.55
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel 60 Plus (+) Pertuzumab 1050Docetaxel 75 + Pertuzumab 1050Docetaxel 75 + Pertuzumab 420Docetaxel 100 + Pertuzumab 420Total
Female20136
Male425213
08

Study locations

2 sites
  • Rotterdam, 3075 EA, Netherlands
  • Sutton, SM2 5PT, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Apr 2006 and a completion of Apr 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 9 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2015
First posted
Jul 3, 2015
Start
Feb 2004
Primary completionActual
Apr 2006
CompletionActual
Apr 2006
Results first posted
Nov 25, 2015
Last update
May 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02490475
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 3, 2015
Start date
Feb 2004
Primary completion
Apr 2006
Completion
Apr 2006
Results posted
Nov 25, 2015
Last update
May 17, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion